Procaps Group and Genomma Lab Internacional, S.A.B. de C.V. announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America. Through this partnership, Procaps will manufacture and Genomma will market and distribute the products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | +0.76% | -5.62% | -34.89% |
May. 20 | Procaps Group Gets Nasdaq Noncompliance Notice for Late Filing of Annual Report | MT |
May. 01 | Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
16.66 MXN | -4.75% | -6.25% | 860M | ||
2.65 USD | +0.76% | -5.62% | 297M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.89% | 297M | |
+47.54% | 765B | |
-6.69% | 354B | |
+19.54% | 331B | |
+8.90% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+4.84% | 164B | |
-2.72% | 162B |
- Stock Market
- Equities
- PROC Stock
- News Procaps Group S.A.
- Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America